Coloplast’s Q3 23 earnings missed consensus, reporting revenue of DKK6.11bn, up 8% organically. The Chronic care business excelled with ~8.5% growth, driven by the strong performances in China and the US. Urology maintained stability with 7% growth, despite challenging comparisons. However, Wound & Skin disappointed due to lower growth in Europe and timing issues. Adjusted EBIT margin contracted to 28%, and will trigger a downward adjustment to our FY23 margin estimates.
23 Aug 2023
Q3 23: inflation still bites; FY23 margin miss likely
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 23: inflation still bites; FY23 margin miss likely
- Published:
23 Aug 2023 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast’s Q3 23 earnings missed consensus, reporting revenue of DKK6.11bn, up 8% organically. The Chronic care business excelled with ~8.5% growth, driven by the strong performances in China and the US. Urology maintained stability with 7% growth, despite challenging comparisons. However, Wound & Skin disappointed due to lower growth in Europe and timing issues. Adjusted EBIT margin contracted to 28%, and will trigger a downward adjustment to our FY23 margin estimates.